Experience on the long-term use of canakinumab in mevalonate kinase deficiency: A case series

Int J Rheum Dis. 2024 May;27(5):e15192. doi: 10.1111/1756-185X.15192.
No abstract available

Publication types

  • Letter
  • Case Reports

MeSH terms

  • Adolescent
  • Antibodies, Monoclonal, Humanized* / therapeutic use
  • Child
  • Female
  • Genetic Predisposition to Disease
  • Humans
  • Interleukin-1beta / antagonists & inhibitors
  • Interleukin-1beta / blood
  • Male
  • Mevalonate Kinase Deficiency* / diagnosis
  • Mevalonate Kinase Deficiency* / drug therapy
  • Time Factors
  • Treatment Outcome

Substances

  • canakinumab
  • Antibodies, Monoclonal, Humanized
  • Interleukin-1beta

Grants and funding